Education
About Us
Working with TipRanks
Follow Us
Universe Pharmaceuticals (UPC)
NASDAQ:UPC
UPC Stock Chart & Stats
$4.22
-$0.02(-3.13%)
At close: 4:00 PM EST
$4.22
-$0.02(-3.13%)
Day’s Range― - ―
52-Week Range$2.51 - $11.00
Previous CloseN/A
Volume250.22K
Average Volume (3M)955.25K
Market Cap
$1.53M
Enterprise Value-$22.76M
Total Cash (Recent Filing)$33.59M
Total Debt (Recent Filing)$9.26M
Price to Earnings (P/E)―
Beta1.66
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding563,338
10 Day Avg. Volume2,486,504
30 Day Avg. Volume955,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-14.86
Enterprise Value/Revenue-1.27
Enterprise Value/Gross Profit-3.61
Enterprise Value/Ebitda7.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageModest absolute debt and a low debt-to-equity ratio provide durable financial flexibility. With limited leverage the firm has more runway to fund operations, restructure costs or pursue strategic investments without immediate refinancing pressure, supporting near-term solvency while losses persist.
Gross Margin RecoveryA material improvement in gross margin suggests better product mix, pricing or cost control at the core level. Sustained higher gross margins improve the ability to achieve operating leverage as volumes stabilize, lowering the revenue threshold needed for profitability over the medium term.
Distribution Footprint & Market FocusA broad provincial distribution network and focus on elderly-health products align with structural demographic demand in China. This scalable reach supports recurring sales, third-party distribution revenue and cross-selling opportunities that can underpin recovery if execution and demand stabilize.
Bears Say
Multi-year Revenue DeclineA persistent top-line decline and four straight years of net losses indicate structural demand or competitive pressures. Shrinking revenue impairs scale, raises per-unit fixed costs, and reduces strategic optionality, making it harder to fund R&D or commercialization without a clear turnaround in demand.
Negative Cash GenerationConsistently negative operating and free cash flows show the business consumes cash rather than generating it, constraining reinvestment in growth and increasing reliance on external financing. This raises dilution and refinancing risk and limits the company's ability to execute longer-term strategies.
Dual-Class Governance ShiftImplementing a dual-class structure is a lasting governance change that can entrench insiders and weaken minority protections. Over the medium term this may deter institutional investors, reduce governance oversight, and complicate future equity raises or strategic deals that require broad shareholder support.
Universe Pharmaceuticals News
UPC FAQ
What was Universe Pharmaceuticals’s price range in the past 12 months?
Universe Pharmaceuticals lowest stock price was $2.51 and its highest was $11.00 in the past 12 months.
What is Universe Pharmaceuticals’s market cap?
Universe Pharmaceuticals’s market cap is $1.53M.
When is Universe Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Universe Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Universe Pharmaceuticals overvalued?
According to Wall Street analysts Universe Pharmaceuticals’s price is currently Overvalued.
Does Universe Pharmaceuticals pay dividends?
Universe Pharmaceuticals does not currently pay dividends.
What is Universe Pharmaceuticals’s EPS estimate?
Universe Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Universe Pharmaceuticals have?
Universe Pharmaceuticals has 563,338 shares outstanding.
What happened to Universe Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Universe Pharmaceuticals?
Currently, no hedge funds are holding shares in UPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Universe Pharmaceuticals
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Technical Analysis
China Pharma Holdings
―
RedHill Biopharma
―
China SXT Pharmaceuticals
―
PainReform
―
Shuttle Pharmaceuticals Holdings, Inc.
―